Impaired interferon-γ production in response to live bacteria and Toll-like receptor agonists in patients with ataxia telangiectasia

Clinical and Experimental Immunology

Volumn 146, Issue 3, 2006, Pages 381-389

  Reichenbach, J ^a   Schubert, R ^b   Feinberg, J ^c   Beck, O ^a   Rosewich, M ^b   Rose, M A ^b   Zielen, S ^b  

^a UNIVERSITY CHILDREN S HOSPITAL   (Switzerland)

^b GOETHE UNIVERSITY   (Germany)

^c UNIVERSITÉ PARIS DESCARTES   (France)

Author keywords

Ataxia telangiectasia; IFN ; NK cell; T cell; Toll like receptor (TLR) agonists

Indexed keywords

ANTIGEN; BACTERIUM LIPOPOLYSACCHARIDE; BCG VACCINE; GAMMA INTERFERON; INTERLEUKIN 12; RECEPTOR BLOCKING AGENT; TOLL LIKE RECEPTOR;

ADULT; ARTICLE; ATAXIA TELANGIECTASIA; BLOOD ANALYSIS; CELLULAR IMMUNITY; CLINICAL ARTICLE; CONTROLLED STUDY; FEMALE; HUMAN; HUMAN CELL; IMMUNOCOMPETENT CELL; INTERFERON PRODUCTION; MALE; MYCOBACTERIUM BOVIS; NATURAL KILLER CELL; PRIORITY JOURNAL; STAPHYLOCOCCUS AUREUS; STAPHYLOCOCCUS INFECTION; T LYMPHOCYTE;

ADOLESCENT; ADULT; ATAXIA TELANGIECTASIA; CELLS, CULTURED; CHILD; CHILD, PRESCHOOL; FEMALE; HUMANS; IMMUNE TOLERANCE; INTERFERON TYPE II; INTERLEUKIN-10; INTERLEUKIN-12; KILLER CELLS, NATURAL; LIPOPOLYSACCHARIDES; LYMPHOCYTE ACTIVATION; MACROPHAGE ACTIVATION; MALE; MONOCYTES; MYCOBACTERIUM BOVIS; PHYTOHEMAGGLUTININS; STAPHYLOCOCCUS AUREUS; T-LYMPHOCYTE SUBSETS; TOLL-LIKE RECEPTORS; TUMOR NECROSIS FACTOR-ALPHA;

EID: 33750894822     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2006.03221.x     Document Type: Article

References (42)

1. Lavin MF, Shiloh Y. The genetic defect in ataxia-telangiectasia. Annu Rev Immunol 1997; 15:177-202.
2. Carbonari M, Cherchi M, Paganelli R et al. Relative increase of T cells expressing the gamma/delta rather than the alpha/beta receptor in ataxia-telangiectasia. N Engl J Med 1990; 322:73-6.
3. + T cell subsets in ataxia telangiectasia. Clin Exp Immunol 2002; 129:125-32.
4. Liew FY, Xu D, Brint EK, O'Neill LA. Negative regulation of toll-like receptor-mediated immune responses. Nat Rev Immunol 2005; 5:446-58.
5. Hopkins PA, Sriskandan S. Mammalian Toll-like receptors: to immunity and beyond. Clin Exp Immunol 2005; 140:395-407.
6. Boehm U, Klamp T, Groot M, Howard JC. Cellular responses to interferon-gamma. Annu Rev Immunol 1997; 15:749-95.
7. Frucht DM, Fukao T, Bogdan C, Schindler H, O'Shea JJ, Koyasu S. IFN-gamma production by antigen-presenting cells: mechanisms emerge. Trends Immunol 2001; 22:556-60.
8. Feinberg J, Fieschi C, Doffinger R et al. Bacillus Calmette-Guerin triggers the IL-12/IFN-gamma axis by an IRAK-4- and NEMO-dependent, non-cognate interaction between monocytes, NK, and T lymphocytes. Eur J Immunol 2004; 34:3276-84.
9. Gerosa F, Paganin C, Peritt D et al. Interleukin-12 primes human CD4 and CD8 T cell clones for high production of both interferon-gamma and interleukin-10. J Exp Med 1996; 183:2559-69.
10. Hartel C, Adam N, Strunk T, Temming P, Muller-Steinhardt M, Schultz C. Cytokine responses correlate differentially with age in infancy and early childhood. Clin Exp Immunol 2005; 142:446-53.
11. Miyawaki T, Seki H, Taga K, Sato H, Taniguchi N. Dissociated production of interleukin-2 and immune (gamma) interferon by phytohaemagglutinin stimulated lymphocytes in healthy infants. Clin Exp Immunol 1985; 59:505-11.
12. Chipeta J, Komada Y, Zhang XL et al. CD4+ and CD8+ cell cytokine profiles in neonates, older children, and adults: increasing T helper type 1 and T cytotoxic type 1 cell populations with age. Cell Immunol 1998; 183:149-56.
13. O'Connell M, Belanger B, Haaland P. Calibration and assay development using the four-parameter logistic model. Chemometr Intell Lab Syst 1993; 20:97-114.
14. Reichenbach J, Schubert R, Schwan C, Muller K, Bohles HJ, Zielen S. Anti-oxidative capacity in patients with ataxia telangiectasia. Clin Exp Immunol 1999; 117:535-9.
15. Schubert R, Reichenbach J, Royer N, Pichler M, Zielen S. Spontaneous and oxidative stress-induced programmed cell death in lymphocytes from patients with ataxia telangiectasia (AT). Clin Exp Immunol 2000; 119:140-7.
16. Barzilai A, Rotman G, Shiloh Y. ATM deficiency and oxidative stress: a new dimension of defective response to DNA damage. DNA Repair (Amst) 2002; 1:3-25.
17. Carnaud C, Lee D, Donnars O et al. Cutting edge: cross-talk between cells of the innate immune system: NKT cells rapidly activate NK cells. J Immunol 1999; 163:4647-50.
18. Farrar MA, Schreiber RD. Themolecular cell biology of interferon-gamma and its receptor. Annu Rev Immunol 1993; 11:571-611.
19. Trinchieri G. Proinflammatory and immunoregulatory functions of interleukin-12. Int Rev Immunol 1998; 16:365-96.
20. Kaplan DH, Shankaran V, Dighe AS et al. Demonstration of an interferon gamma-dependent tumor surveillance system in immunocompetent mice. Proc Natl Acad Sci USA 1998; 95:7556-61.
21. Ikeda H, Old LJ, Schreiber RD. The roles of IFN gamma in protection against tumor development and cancer immunoediting. Cytokine Growth Factor Rev 2002; 13:95-109.
22. Fehniger TA, Cooper MA, Nuovo GJ et al. CD56 bright natural killer cells are present in human lymph nodes and are activated by T cell-derived IL-2: a potential new link between adaptive and innate immunity. Blood 2003; 101:3052-7.
23. Kemp K, Hviid L, Kharazmi A, Kemp M. Interferon-gamma production by human T cells and natural killer cells in vitro in response to antigens from the two intracellular pathogens Mycobacterium tuberculosis and Leishmania major. Scand J Immunol 1997; 46:495-9.
24. Cooper MA, Fehniger TA, Caligiuri MA. The biology of human natural killer-cell subsets. Trends Immunol 2001; 22:633-40.
25. Tato CM, Martins GA, High FA, DiCioccio CB, Reiner SL, Hunter CA. Cutting edge: innate production of IFN-gamma by NK cells is independent of epigenetic modification of the IFN-gamma promoter. J Immunol 2004; 173:1514-17.
26. Vitale M, Della Chiesa M, Carlomagno S et al. The small subset of CD56brightCD16- natural killer cells is selectively responsible for both cell proliferation and interferon-gamma production upon interaction with dendritic cells. Eur J Immunol 2004; 34:1715-22.
27. Batoni G, Esin S, Favilli F et al. Human CD56bright and CD56dim natural killer cell subsets respond differentially to direct stimulation with Mycobacterium bovis bacillus Calmette-Guerin. Scand J Immunol 2005; 62:498-506.
28. Paganelli R, Capobianchi MR, Matricardi PM et al. Defective interferon-gamma production in ataxia-telangiectasia. Clin Immunol Immunopathol 1984; 32:387-91.
29. Paganelli R, Capobianchi MR, Ensoli B et al. Evidence that defective gamma interferon production in patients with primary immunodeficiencies is due to intrinsic incompetence of lymphocytes. Clin Exp Immunol 1988; 72:124-9.
30. Giovannetti A, Mazzetta F, Caprini E et al. Skewed T-cell receptor repertoire, decreased thymic output, and predominance of terminally differentiated T cells in ataxia telangiectasia. Blood 2002; 100:4082-9.
31. Melvin AJ, McGurn ME, Bort SJ, Gibson C, Lewis DB. Hypomethylation of the interferon-gamma gene correlates with its expression by primary T-lineage cells. Eur J Immunol 1995; 25:426-30.
32. White GP, Watt PM, Holt BJ, Holt PG. Differential patterns of methylation of the IFN-gamma promoter at CpG and non-CpG sites underlie differences in IFN-gamma gene expression between human neonatal and adult CD45RO- T cells. J Immunol 2002; 168:2820-7.
33. Katamura K, Fukui T, Kiyomasu T et al. IL-4 and prostaglandin E2 inhibit hypomethylation of the 5′ regulatory region of IFN-gamma gene during differentiation of naive CD4+ T cells. Mol Immunol 1998; 35:39-45.
34. Thiel A, Schmitz J, Miltenyi S, Radbruch A. CD45RA-expressing memory/effector Th cells committed to production of interferon-gamma lack expression of CD31. Immunol Lett 1997; 57:189-92.
35. Reichenbach J, Schubert R, Schindler D, Muller K, Bohles H, Zielen S. Elevated oxidative stress in patients with ataxia telangiectasia. Antioxid Redox Signal 2002; 4:465-9.
36. Malmberg KJ, Arulampalam V, Ichihara F et al. Inhibition activated/memory (CD45RO(+)) T cells by oxidative stress associated with block of NF-kappaB activation. J Immunol 2001; 167:2595-601.
37. Valinluck V, Tsai HH, Rogstad DK, Burdzy A, Bird A, Sowers LC. Oxidative damage to methyl-CpG sequences inhibits the binding of the methyl-CpG binding domain (MBD) of methyl-CpG binding protein 2 (MeCP2). Nucl Acids Res 2004; 32:4100-8.
38. Rink L, Cakman I, Kirchner H. Altered cytokine production in the elderly. Mech Ageing Dev 1998; 102:199-209.
39. Tchirkov A, Lansdorp PM. Role of oxidative stress in telomere shortening in cultured fibroblasts from normal individuals and patients with ataxia-telangiectasia. Hum Mol Genet 2003; 12:227-32.
40. Neuber K, Schmidt S, Mensch A. Telomere length measurement and determination of immunosenescence-related markers (CD28, CD45RO, CD45RA, interferon-gamma and interleukin-4) in skin-homing T cells expressing the cutaneous lymphocyte antigen: indication of a non-ageing T-cell subset. Immunology 2003; 109:24-31.
41. Mocchegiani E, Malavolta M. NK and NKT cell functions in immunosenescence. Aging Cell 2004; 3:177-84.
42. Shearer WT, Rosenblatt HM, Gelman RS et al. Lymphocyte subsets in healthy children from birth through 18 years of age: the Pediatric AIDS Clinical Trials Group P1009 study. J Allergy Clin Immunol 2003; 112:973-80.